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Worldwide trends in hypertension prevalence and progress 
in treatment and control from 1990 to 2019: a pooled 
analysis of 1201 population-representative studies with 
104 million participants
NCD Risk Factor Collaboration (NCD-RisC)*
Summary
Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively 
control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, 
and control from 1990 to 2019 for 200 countries and territories.
Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with 
measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic 
blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for 
hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the 
proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for 
hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model 
allowed for trends over time to be non-linear and to vary by age.
Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible 
interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) 
million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence 
was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries 
in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income 
countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for 
women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and 
Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis 
of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people 
with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates 
were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, 
Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, 
Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in 
these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and 
control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa 
and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and 
recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran.
Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially 
across countries, with some middle-income countries now outperforming most high-income nations. The 
dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and 
control is achievable not only in high-income countries but also in low-income and middle-income settings.
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Introduction
Hypertension, along with pre-hypertension and other 
hazardously high blood pressure, is responsible for 
8·5 million deaths from stroke, ischaemic heart 
disease, other vascular diseases, and renal disease 
worldwide.1,2 Hypertension can be detected in the 
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community and primary care facilities, and several 
effective drugs are available at fairly low cost for treating 
patients with hypertension and reducing the risk of 
its sequelae.1,3–5 Improving the effective coverage of 
treatment for patients with hypertension is an objective 
of many global, regional, and national initiatives, and 
programmes.
Comparable data on hypertension detection, treat-
ment, and control are needed to learn from good 
practice to guide health system programmes. No 
Research in context
Evidence before this study
We searched MEDLINE (via PubMed) for articles published 
from inception to Jan 15, 2021, using the search terms 
((hypertension[Title] AND (((medication OR treatment) AND 
control) OR aware*) AND “blood pressure”) OR 
(cardiovascular[Title] AND risk factor*[Title] AND “blood 
pressure” AND (((medication OR treatment) AND control) OR 
aware*))) AND (trend* OR global OR worldwide) NOT 
patient*[Title]. No language restrictions were applied. We found 
a few multi-country studies that reported hypertension 
prevalence, treatment, and control. These studies used up to 
135 data sources that had sampled from national or sub-national 
populations or data from small communities. Few multi-country 
studies reported trends over time. The largest of these analyses 
covered snapshots in 2000 and 2010 and grouped countries into 
high income versus low income and middle income. We also 
found several studies that analysed trends in individual countries. 
To our knowledge, there is no study on long-term trends in, 
nor the contemporary levels of, hypertension prevalence, 
detection, treatment, and control that covers the entire world.
Added value of this study
To our knowledge, this study is the first comprehensive global 
analysis of trends in hypertension prevalence, detection, 
treatment, and control that covers all countries worldwide. 
The data used in the study were from 184 countries, together 
covering 99% of the global population, and were subject to 
rigorous inclusion and exclusion criteria. Data were analysed 
using a standardised protocol and were pooled using a 
statistical model designed to incorporate how hypertension 
and its care and control vary in relation to age, geography, 
and time.
Implications of all the available evidence
Hypertension care—including detection, treatment, and 
control—varies substantially worldwide and even within the 
same region of the world. Sub-Saharan Africa, Oceania, and 
south Asia have the lowest rates of detection, treatment, 
and control and many countries in these regions have seen little 
improvement in these outcomes over the past 30 years. 
The large improvements observed in some upper-middle-
income and recently high-income countries show that the 
expansion of universal health coverage and primary care can be 
leveraged to enhance hypertension care and reduce the health 
burden of this condition.
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comparable global data exist to assess which countries 
have high versus low rates of detection, treatment, and 
control, and how these measures have changed over 
time. We present consistent national, regional, and 
global estimates of trends in hypertension prevalence, 
detection, treatment and control from 1990 to 2019 for 




We used data from 1990 to 2019, collated by the NCD 
Risk Factor Collaboration (NCD-RisC), as detailed 
previously6 and summarised in the appendix (pp 2–3). 
The inclusion criteria were that (1) data were collected 
using a probabilistic sampling method with a defined 
sampling frame; (2) data were from population samples 
at the national, sub-national (covering one or more sub-
national regions), or community (one or a small number 
of communities) level; (3) systolic blood pressure and 
diastolic blood pressure were measured; and (4) data on 
hypertension treatment were available.
Studies were excluded if they (1) included or excluded 
participants on the basis of health status; (2) were 
done only among minority ethnic groups or specific 
educational, occupational, or other socioeconomic 
groups; (3) recruited participants through health 
facilities, except studies whose sampling frame was 
health insurance schemes in countries where at least 
80% of the population were insured, and studies based 
on primary care systems in high-income and central 
European countries with universal insurance; or (4) had 
not measured blood pressure. A list of data sources and 
their characteristics is provided in the appendix (pp 7–30).
We established whether a participant had been diagnosed 
with hypertension using questions worded as variations of 
“Have you ever been told by a doctor or other health 
professional that you had hypertension, also called high 
See Online for appendix
(Figure 2 continues on next page)
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blood pressure?” We assessed whether a person was taking 
medication for hypertension using questions worded as 
variations of “Are you currently taking any medicines, 
tablets, or pills for high blood pressure?” or “In the past 
2 weeks, have you taken any drugs (medication) for raised 
blood pressure prescribed by a doctor or other health 
worker?” In studies that gathered information on 
prescribed medicines, we used survey information to 
establish that the purpose of taking a blood pressure-
lowering drug was specifically to treat hypertension.
Outcomes
Our primary outcomes were prevalence of hypertension, 
the proportion of people with hypertension who reported a 
previous hypertension diagnosis (detection), who were 
taking medication for hypertension (treatment), and whose 
blood pressure was controlled (control).7 Hyper tension 
was defined as having systolic blood pressure 140 mm Hg 
or greater, diastolic blood pressure 90 mm Hg or greater, 
or taking medication for hypertension. Control was defined 
as taking medication for hypertension and having systolic 
blood pressure less than 140 mm Hg and diastolic blood 
pressure less than 90 mm Hg. We also report the proportion 
of people with hypertension who were undiagnosed or 
untreated with systolic blood pressure 160 mm Hg or 
greater or diastolic blood pressure 100 mm Hg or greater. 
We restricted our analysis to men and women aged 
30–79 years because hypertension prevalence is relatively 
low before age 30 years and because guidelines differ in 
thresholds and treatment targets in older ages.8
Figure 2: Prevalence of hypertension in 2019 and change from 1990 to 2019 in women and men
Prevalence of hypertension in 2019 and change from 1990 to 2019 in women (A) and men (B). The density plot alongside each map shows the distribution of estimates across countries. The top right 
graph in each panel shows results ordered within regions and super-regions with 95% credible intervals. The bottom right graph in each panel shows the change from 1990 to 2019 in hypertension 
prevalence in relation to the uncertainty of the change measured by posterior SD. Shaded areas show the posterior probability of an estimated increase or decrease being a true increase or decrease. 
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Statistical analysis
We calculated the prevalence, detection, treatment, and 
control of hypertension by sex and age group for each 
study. The denominators for detection, treatment, and 
control were the number of people with hypertension. 
When applicable, we used survey sample weights and 
accounted for complex survey design.
We applied a Bayesian hierarchical model to these 
sex-specific and age-specific data to estimate the pri-
mary outcomes by country, year, and age. All analyses 
Figure 3: Hypertension treatment cascade in 2019, for women and men globally and by region
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were done separately by sex and for each primary 
outcome. The model is described in detail in a statistical 
paper9 and related substantive papers6,10 and sum-
marised in the appendix (pp 4–6). Countries were 
grouped into 21 regions, which were further grouped 
into nine super-regions (appendix pp 31–32). In the 
hierarchical model, estimates for a country-year were 
informed by its own data if available, by data from other 
years in the same country, and from other countries, 
especially those from the same region and super-
region. The extent to which estimates for each country-
year were influenced by data from other years and 
countries depended on whether the country had data, 
sample size, whether data were national, and the 
within-country and within-region variability of the 
available data.
The model allowed for non-linear time trends and non-
linear age patterns. For this analysis, we adapted the model 
to allow time trends to vary by age (appendix pp 4–6) 
because how hypertension and its detection, treatment, 
and control have changed over time depends on age.11,12 
The model also accounted for the possibility that 
hypertension prevalence, detection, treatment, and control 
in sub-national and community studies might sys-
tematically differ from those in nationally representative 
studies, or might have larger variation than in national 
studies, so that national data had a larger influence on the 
estimates than sub-national or community data did with 
similar sample sizes. Finally, the model accounted and 
adjusted for how much studies that were done in only 
rural or urban areas differed from national studies.
We fitted the model using the Markov chain Monte Carlo 
(MCMC) algorithm implemented in R (version 3.6.0), 
and obtained 50 000 post-burn-in samples from the 
posterior distribution of model parameters. We kept 
every 10th sample, and the resultant 5000 samples 
(Figure 4 continues on next page)
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were used to obtain the posterior distributions of the 
primary outcomes. The reported 95% credible intervals 
(CrIs) are the 2·5th to 97·5th percentiles of the posterior 
distributions. We calculated age-standardised hyper-
tension prevalence, and the rates of detection, treatment, 
and control, by weighting age-specific estimates using 
the WHO standard popula tion.13 When calculating age-
standardised detection, treatment, and control rates, we 
also accounted for the age pattern of hypertension 
prevalence, which appears in the denominator, by 
using the combination of WHO standard population 
weights and age-specific hypertension prevalence in each 
country and year to weight age-specific estimates. 
Estimates for regions, super-regions, and the world were 
calculated by weighting the age-specific and sex-specific 
posterior samples for the constituent countries with the 
corres ponding age-specific and sex-specific national 
populations; the population data were from World 
Population Prospects (2019 revision).14 The estimates in 
each country and region and in each year are for the 
corresponding national and regional population in that 
year. We used consistent analysis and presentation units 
over the entire 30-year period. For countries that were 
formed during these 30 years (eg, South Sudan and 
Montenegro), estimates apply to an equivalent territory 
for the years before their formation.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
We used 1201 studies carried out from 1990 to 2019 with 
data on 104 million participants aged 30–79 years. Of 
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previous diagnosis. 184 countries, covering 99% of the 
global population, had at least one data source (figure 1), 
and 131 countries, covering 94% of the world’s population, 
had two or more data sources. Regionally, data avail-
ability ranged from 2·2 data sources per country in 
sub-Saharan Africa to 26·0 data sources per country in 
the high-income Asia-Pacific region (figure 1).
In 2019, the global age-standardised prevalence of 
hypertension in adults aged 30–79 years was 32% 
(95% CrI 30–34) in women and 34% (32–37) in men, 
similar to 1990 levels of 32% (30–35) in women and 
32% (30–35) in men (figure 2). The stable global 
prevalence was a net effect of a decrease in high-
income countries, and for women also in central and 
eastern Europe, and an increase in some low-income and 
middle-income countries. The decline was greater than 
12 percentage points in women in several high-income 
countries (posterior probability [PP] of the observed 
decline being a true decline >0·98 for all country and sex 
combinations; figure 2). By contrast, age-standardised 
prevalence increased, or at best remained unchanged, 
in most low-income and middle-income countries 
(figure 2). The increase was 10–15 percentage points 
among men in three countries and among women in 
four countries (PP 0·85–0·99).
Nationally, prevalence of hypertension in 2019 was 
lowest in Canada and Peru for both men and women; in 
Taiwan, South Korea, Japan, and some countries in 
western Europe for women; and in some low-income 
and middle-income countries for men (figure 2). 
Age-standardised prevalence in all of these countries was 
less than 24% for women and less than 25% for men 
in 2019 (figure 2). Hypertension prevalence was highest 
throughout central and eastern Europe, central Asia, 
Oceania, southern Africa, and some countries in 
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in two countries and men in nine countries, age-
standardised prevalence surpassed 50% (figure 2).
Globally, 41% (95% CrI 38–45) of women and 
51% (48–54) of men with hypertension did not report a 
previous diagnosis (figure 3). The treatment rate was 
47% (43–51) in women and 38% (35–41) in men. Less 
than half of those treated had achieved hypertension 
control, leading to global control rates of 23% (20–27) for 
women and 18% (16–21) for men with hypertension 
(figure 3). 27–34% of women and men in the high-
income western and Asia-Pacific regions with hyper-
tension were not aware of their condition, an additional 
10–14% were untreated, and 21% did not achieve control 
(figure 3). The detection gap, together with sequential 
low treatment coverage and effectiveness, led to control 
rates ranging from 31% in men in the high-income 
Asia-Pacific to 43% in women in the high-income 
western region (figure 3). Control rates were below 13% 
in sub-Saharan Africa and Oceania, where 50–60% of 
women and nearly 70% of men with hypertension were 
not aware of their condition; detection, treatment and 
control rates in south Asia were only slightly higher 
(figure 3). In all regions the coverage of treatment 
increased with age, being highest in those aged 65 years 
and older (appendix pp 50–51).
Nationally, hypertension treatment and control were 
highest in South Korea, Canada, and Iceland, where more 
than 70% of women and men with hypertension were 
treated and over half had their hypertension controlled 
(figure 4). Treatment and control rates were also high in 
Figure 4: Proportion of women and men with hypertension who used treatment and whose blood pressure was controlled in 2019, and change from 1990 to 2019
See the appendix (pp 52–53) for control rates among those on treatment and for a comparison of treatment and control rates (pp 54–55). The density plot alongside each map shows the distribution 
of estimates across countries. The top right graph in each panel shows the results ordered within regions and super-regions with their 95% credible intervals. The bottom right graph in each panel 
shows the change from 1990 to 2019 in hypertension treatment and control rates in relation to the uncertainty of the change measured by posterior SD. Shaded areas show the posterior probability of 
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the USA, Costa Rica, Germany, Portugal, and Taiwan. At 
the other extreme, treatment rates were less than 25% for 
women and less than 20% for men in Nepal, Indonesia, 
and several countries in sub-Saharan Africa and Oceania 
(figure 4). Control rates were less than 10% for women 
and men in these countries and for men in some countries 
in the Middle East and north Africa, central and south Asia, 
and eastern Europe (figure 4). The proportion of those 
treated who achieved control varied by more than four 
times across countries (appendix pp 54–55). In particular, 
many countries in eastern Europe, central and east Asia, 
and the Middle East and north Africa had somewhat 
high treatment rates but low control, contrasting with 
findings in high-income countries and some countries in 
Latin America and the Caribbean, where treatment and 
control tracked more closely (appendix pp 54–55).
Hypertension treatment and control improved in most 
countries since 1990, but we found little improvement in 
many countries in sub-Saharan Africa and Oceania 
(figure 4). Improvements were largest in high-income 
countries and central Europe, with some countries 
expanding treatment and control by more than 
30 percentage points (figure 4). Some upper-middle-
income countries and recently high-income countries in 
other regions (eg, Costa Rica, Taiwan, Kazakhstan, South 
Africa, Brazil, Chile, Turkey, and Iran) also substantially 
enhanced treatment and control (figure 4). Hypertension 
treatment and control rates were lower in men than in 
women in most countries (appendix pp 56–57). The male 
disadvantage in treatment was smaller in high-income 
countries than elsewhere and, in a few countries, we 
found the reverse of this pattern (appendix pp 56–57).
In 2019, the proportion of people with systolic blood 
pressure 160 mm Hg or greater or diastolic blood pressure 
100 mm Hg or greater but were not diagnosed or treated 
was below 10% in countries with high treatment coverage, 
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and as low as 4% among women in South Korea (figure 5). 
Between one in four to one in three women and men with 
hypertension in many sub-Saharan African and Oceanian 
countries and in some countries in central, south, and 
southeast Asia had systolic blood pressure 160 mm Hg or 
greater or diastolic blood pressure 100 mm Hg or greater 
but were not diagnosed or treated (figure 5).
Despite stable global prevalence, the absolute number 
of people aged 30–79 years with hypertension doubled 
from 331 (95% CrI 306–359) million women and 
317 (292–344) million men in 1990 to 626 (584–668) mil-
lion women and 652 (604–698) million men in 2019 due 
to population growth and ageing (figure 6). Similarly, 
despite improvement in detection, treatment, and control 
rates, more people did not achieve effective control 
in 2019 than in 1990 because of the large increase in the 
number of people with hypertension (figure 6).
In high-income western and Asia-Pacific regions and 
in central and eastern Europe, the opposite effects of 
declining prevalence and population growth and ageing 
led to a small net increase in the number of people with 
hypertension (figure 6). The improvements in treatment 
and control from 1990 to 2019 shifted many of those with 
hypertension in these regions from being untreated to 
being treated and having their hypertension controlled 
(figure 6). These improvements lowered the absolute 
number of those who were not treated or whose hyper-
tension was not effectively controlled (figure 6).
Figure 5: Proportion of women and men with hypertension who had systolic blood pressure 160 mm Hg or greater or diastolic blood pressure 100 mm Hg or greater but were not diagnosed 
or treated, in 2019, and change from 1990 to 2019
The density plot alongside each map shows the distribution of estimates across countries. The top right graph in each panel shows the results ordered within regions and super-regions with their 
95% credible intervals. The bottom right graph in each panel shows the change from 1990 to 2019 in the proportion of people with hypertension who had systolic blood pressure 160 mm Hg or 
greater or diastolic blood pressure 100 mm Hg or greater but were not diagnosed or treated, in relation to the uncertainty of the change measured by posterior SD. Shaded areas show the posterior 
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In 2019, over 1 billion people with hypertension 
(82% of all people with hypertension in the world) lived 
in low-income and middle-income regions (figure 6). 
This number was much larger than the number in 1990 
because prevalence remained unchanged or increased 
and the population grew and became older. In 
sub-Saharan Africa, Oceania, and south Asia, most of 
the increase was in those without a previous diagnosis, 
whereas in east and southeast Asia and Latin America 
and the Caribbean the number of people in this category 
increased slightly until the mid-2000s before flattening. 
Since then, many more of those with hypertension have 
been detected, treated, and controlled (figure 6).
Discussion
Our novel comprehensive analysis of hypertension 
prevalence and care has shown that since 1990 the 
number of people with hypertension worldwide has 
doubled, with most of the increase occurring in low-
income and middle-income regions. In high-income 
countries, prevalence has declined while health systems 
have achieved treatment rates of up to 80% and control 
rates of up to 60%. Middle-income countries in Latin 
America; east and southeast Asia; and central Asia, the 
Middle East, and north Africa have also enhanced the 
detection and treatment of hypertension. Some of these 
countries, such as Costa Rica, now outperform most 
high-income nations in hypertension treatment and 
control. Low detection and treatment rates persist in the 
world’s poorest nations, especially in sub-Saharan Africa, 
Oceania, and south Asia. Together with the increasing 
number of people who have hypertension, these low 
detection and treatment rates will shift an increasing 
share of the burden of vascular and renal conditions to 
these regions.
To our knowledge, no previous study of trends in 
hypertension prevalence, detection, treatment, and 
control covers all countries in the world. Our results are 
consistent with a multi-country study that reported for 
2000 and 2010,15 in terms of higher treatment and 
control in high-income countries than in low-income 
and middle-income countries, but our national results 
show that substantial variability exists at any level 
of economic development, with some upper-middle-
income countries having treatment and control rates as 
good as, or better than, those in some high-income 
countries. The findings of a study16 on 44 low-income 
and middle-income countries were consistent with ours 
in terms of hypertension treatment rates being highest 
in Latin America and lowest in sub-Saharan Africa; 
although, this study did not have data on trends or 
from high-income countries. Our finding on variable 
improvement in rates of hypertension treatment in 
high-income countries is consistent with a previous 
multi-country study.12
The strengths of our study include its scope of 
presenting consistent and comparable global estimates 
of hypertension prevalence, treatment, and control; the 
Figure 6: Trends in the number of people with hypertension who reported a diagnosis, who used treatment, and whose blood pressure was effectively 
controlled, globally and by region, 1990–2019
See the appendix (pp 58–60) for trends in the percentage of people with hypertension who reported a diagnosis, who had treatment, and whose blood pressure was 
























































































































www.thelancet.com   Vol 398   September 11, 2021 969
scale and quality of data that were harmonised in 
a rigorous process; and the statistical methods that 
were designed for analysing trends in the hypertension 
treatment cascade. We used data from more than 
1200 studies in 184 countries, covering 99% of the 
world’s population, which is eight times as many studies 
as were in the previous largest analysis.15 We used only 
data from studies that had measured blood pressure to 
avoid bias in self-reported data. We re-analysed data 
according to a standardised protocol and the char-
acteristics and quality of data were rigorously verified 
through repeated checks by NCD-RisC members. We 
used a statistical model that accounted for heterogeneous 
trends by age in hypertension prevalence, detection, 
treatment, and control, and we used all available data, 
while giving more weight to national data than to 
non-national sources.
Similar to all global analyses, our study has some 
limitations. Despite our extensive efforts to identify and 
access data, some countries, especially those in Oceania 
and sub-Saharan Africa, had less data than in other 
regions. Most health surveys collect data on previous 
diagnosis and treatment of hypertension using a 
questionnaire, which may lead to measurement error. 
Validation studies show that recall of hypertension 
diagnosis and medication has good agreement with 
actual medical history (eg, with Cohen’s κ ranging 
between 0·55 and 0·91).17–20 Mercury sphygmomano-
meters were more common in earlier studies, whereas 
studies done after 2000 often used digital oscillometric 
devices. Similarly, studies differed on whether they used 
multiple cuff sizes or one cuff size or whether they 
measured blood pressure more than once. The effect 
of measurement device and protocol on population 
prevalence depends on the circumstances of each study. 
For example, an automated digital device with a standard 
cuff, although not the traditional gold standard in a 
clinical setting, avoids observer bias and increases 
compliance and possibly even response rate, compared 
with a mercury sphygmomanometer with multiple 
cuffs.21 Nonetheless, measurements from different 
devices are not fully comparable. Most health surveys are 
based on one visit to each participant, during which 
blood pressure is measured multiple times, usually after 
a resting period when interviews are done. Hypertension 
prevalence based on data collected in multiple visits 
might be lower than that based on one visit.22 We had 
insufficient comparable data on treatment details such as 
the type of drugs because these data are not consistently 
collected in population-representative surveys. Com-
plementing survey data with data from health facilities 
or prescrip tions could provide such clinically relevant 
details.
Our country results show that preventing hypertension 
and enhancing its detection, treatment, and control is 
feasible not only in high-income countries, but also in 
low-income and middle-income nations. Although the 
nutritional, behavioural, and environmental causes of 
increased blood pressure are well established, little is 
known on which actions and interventions that can be 
widely replicated are responsible for the observed 
reductions in hypertension prevalence.23 Similarly, 
although randomised trials have shown the efficacy of 
hypertension treatment and studies in some countries 
or communities have shown that strategies such as 
simple evidence-based guidelines, the use of non-
physician health workers, and patient follow-ups using 
text messages can improve hypertension care,1,2,24–30 little 
transferable guidance exists on how to achieve high 
rates of detection, treatment, and control for entire 
populations. Implementation research on the role of risk 
factors and health system determinants of hypertension 
care and management requires detailed country-level 
data. Information for seven countries with high rates of 
treatment is summarised in the appendix (pp 47–49).
Over the period of our analysis, hypertension 
prevalence decreased while obesity, which is a risk factor 
for hypertension, increased,6 which implies that hyper-
tension’s dietary and environmental determinants 
must have improved. Reducing salt intake to prevent 
hypertension might be possible through a combination 
of fiscal, regulatory, and possibly behavioural inter-
ventions,31,32 although few examples exist of successful 
national programmes so far. Increased availability and 
consumption of fruits and vegetables33 might partly 
account for the observed declines in hypertension, 
which indicates that making these foods affordable 
(eg, through targeted subsidies for poorer families) and 
accessible (eg, through more efficient supply and storage) 
might be effective for hypertension prevention.
Expanding hypertension detection has been helped by 
both more widespread and regular contact with health 
services and more frequent measurement of blood 
pressure.34,35 Increased health-care use requires universal 
health insurance36–39 and expansion of primary care. In 
some countries, training non-physician health workers in 
the management of non-communicable diseases (NCDs) 
might be needed.24–28 Guidelines, availability of blood 
pressure monitors, and regular health checks and 
screening programmes40–44 facilitate more frequent 
measurement. The expansion of universal health 
coverage and primary care in places with low rates of 
diagnosis, especially sub-Saharan Africa and south Asia, 
provides an opportunity for improving hypertension 
care,45,46 but needs to be accompanied with guidelines,47 
training, and blood pressure monitors in health facilities. 
Improvements in treatment have been helped by some 
of the same factors as those for diagnosis, as well 
as guidelines that recommend progressively lower 
thresholds to initiate treatment and wider availability and 
lower cost of antihypertensive medicines, many of which 
are no longer under a patent.48 Despite this improvement, 
insufficient access to medicines contributes to the low 
treatment rates in some low-income countries.46,49–51
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We also found large variation in hypertension control 
among those who were treated. Understanding the 
reasons for the large variation in real-world effectiveness 
of treatment needs data on both the health-system 
features that enable high-quality care and the type of 
pharmacological approach used—eg, renin-angiotensin-
system inhibitors, calcium-channel blockers, or 
diuretics;52 whether single-pill combination therapy is 
used;53 how much the prescribing physician titrates or 
intensifies treatment when needed; and patient adherence 
to treatment. New technologies such as telemonitoring, 
home blood pressure monitoring, and text message 
reminders might improve adherence,29,54–56 but these mea-
sures can be effective only if patients have uninterrupted 
access to effective medicines.
Hypertension prevention and control can make a 
substantial contribution to achieving the Sustainable 
Development Goals target 3.4 on NCDs.57,58 Some 
countries, such as Canada, Costa Rica, South Korea, and 
Taiwan, have achieved low hypertension prevalence or 
high control through both improved prevention and 
improving every stage of the treatment cascade.30,59 
Universal health insurance has been instrumental in 
achieving high effective coverage but should be com-
plemented with primary care strengthening, evidence-
based hypertension guidelines that are up to date and are 
adapted to the country contexts,8,47 health workforce 
training, and a robust system of drug procurement and 
distribution.30 Programmes should also be regularly 
assessed, both at the population level, as our work has 
done, and in health facilities to ensure accountability and 
stimulate improvement.60
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Brazil)*; Alain Morejon (University of Medical Sciences of Cienfuegos, 
Cuba)*; Luis A Moreno (University of Zaragoza, Spain; CIBEROBN, 
Spain)*; Karen Morgan (Royal College of Surgeons in Ireland, Ireland)*; 
George Moschonis (La Trobe University, Australia)*; 
Malgorzata Mossakowska (International Institute of Molecular and Cell 
Biology, Poland)*; Aya Mostafa (Ain Shams University, Egypt)*; 
Seyed-Ali Mostafavi (Tehran University of Medical Sciences, Iran)*; 
Jorge Mota (University of Porto, Portugal)*; 
Mohammad Esmaeel Motlagh (Ahvaz Jundishapur University of Medical 
Sciences, Iran)*; Jorge Motta (Instituto Conmemorativo Gorgas de 
Estudios de la Salud, Panama)*; Marcos André Moura-dos-Santos 
(University of Pernambuco, Brazil)*; Malay K Mridha (BRAC 
James P Grant School of Public Health, Bangladesh)*; 
Kelias P Msyamboza (WHO Country Office, Malawi)*; Thet Thet Mu 
(Department of Public Health, Myanmar)*; Alfa J Muhihi (Muhimbili 
University of Health and Allied Sciences, Tanzania)*; Maria L Muiesan 
(University of Brescia, Italy)*; Martina Müller-Nurasyid (Ludwig-
Maximilians-Universität München, Germany)*; Neil Murphy 
(International Agency for Research on Cancer, France)*; Jaakko Mursu 
(University of Eastern Finland, Finland)*; Kamarul Imran Musa 
(Universiti Sains Malaysia, Malaysia)*; Sanja Musić Milanović (Croatian 
Institute of Public Health, Croatia; University of Zagreb, Croatia)*; 
Vera Musil (University of Zagreb, Croatia)*; Norlaila Mustafa (Universiti 
Kebangsaan Malaysia, Malaysia)*; Iraj Nabipour (Bushehr University of 
Medical Sciences, Iran)*; Shohreh Naderimagham (Non-Communicable 
Diseases Research Center, Iran)*; Gabriele Nagel (Ulm University, 
Germany)*; Balkish M Naidu (Department of Statistics, Malaysia)*; 
Farid Najafi (Kermanshah University of Medical Sciences, Iran)*; 
Harunobu Nakamura (Kobe University, Japan)*; Jana Námešná (Banska 
Bystrica Regional Authority of Public Health, Slovakia)*; Ei Ei K Nang 
(National University of Singapore, Singapore)*; Vinay B Nangia (Suraj 
Eye Institute, India)*; Sameer Narake (Healis-Sekhsaria Institute for 
Public Health, India)*; Ndeye Coumba Ndiaye (Institut National de la 
Santé et de la Recherche Médicale, France)*; William A Neal 
(West Virginia University, USA)*; Azim Nejatizadeh (Hormozgan 
University of Medical Sciences, Iran)*; Ilona Nenko (Jagiellonian 
University Medical College, Poland)*; Martin Neovius (Karolinska 
Institutet, Sweden)*; Hannelore K Neuhauser (Robert Koch Institute, 
Germany)*; Chung T Nguyen (National Institute of Hygiene and 
Epidemiology, Vietnam)*; Nguyen D Nguyen (University of Medicine 
and Pharmacy at Ho Chi Minh City, Vietnam)*; Quang V Nguyen 
(National Hospital of Endocrinology, Vietnam)*; Quang Ngoc Nguyen 
(Hanoi Medical University, Vietnam)*; Ramfis E Nieto-Martínez 
(LifeDoc Health, USA)*; Teemu J Niiranen (Finnish Institute for Health 
and Welfare, Finland; University of Turku, Finland)*; Yury P Nikitin 
(SB RAS Federal Research Center Institute of Cytology and Genetics, 
Russia)*; Toshiharu Ninomiya (Kyushu University, Japan)*; 
Sania Nishtar (Heartfile, Pakistan)*; Marina A Njelekela (Muhimbili 
University of Health and Allied Science, Tanzania)*; Marianna Noale 
(Institute of Neuroscience of the National Research Council, Italy)*; 
Oscar A Noboa (Universidad de la República, Uruguay)*; 
Ahmad Ali Noorbala (Tehran University of Medical Sciences, Iran)*; 
Teresa Norat (Imperial College London, UK)*; Maria Nordendahl (Umeå 
University, Sweden)*; Børge G Nordestgaard (Copenhagen University 
Hospital, Denmark; University of Copenhagen, Denmark)*; Davide Noto 
(University of Palermo, Italy)*; Natalia Nowak-Szczepanska (PASs 
Hirszfeld Institute of Immunology and Experimental Therapy, Poland)*; 
Mohannad Al Nsour (Eastern Mediterranean Public Health Network, 
Jordan)*; Baltazar Nunes (National Institute of Health Doutor Ricardo 
Jorge, Portugal; NOVA University Lisbon, Portugal)*; Terence W O’Neill 
(University of Manchester, UK)*; Dermot O’Reilly (Queen’s University 
of Belfast, UK)*; Caleb Ochimana (Harvard T H Chan School of Public 
Health, USA)*; Eiji Oda (Tachikawa General Hospital, Japan)*; 
Augustine N Odili (University of Abuja College of Health Sciences, 
Nigeria)*; Kyungwon Oh (Korea Centers for Disease Control and 
Prevention, South Korea)*; Kumiko Ohara (Kindai University, Japan)*; 
Ryutaro Ohtsuka (Japan Wildlife Research Center, Japan)*; Valérie Olié 
(French Public Health Agency, France)*; Maria Teresa A Olinto 
(Universidade do Vale do Rio dos Sinos, Brazil)*; Isabel O Oliveira 
(Federal University of Pelotas, Brazil)*; Mohd Azahadi Omar (Ministry 
of Health, Malaysia)*; Altan Onat (Istanbul University, Turkey; 
deceased)*; Sok King Ong (Ministry of Health, Brunei)*; Lariane M Ono 
(Universidade Federal do Paraná, Brazil)*; Pedro Ordunez 
(Pan American Health Organization, USA)*; Rui Ornelas (University of 
Madeira, Portugal)*; Pedro J Ortiz (Universidad Peruana Cayetano 
Heredia, Peru)*; Clive Osmond (University of Southampton, UK)*; 
Sergej M Ostojic (University of Novi Sad, Serbia)*; Afshin Ostovar 
(Osteoporosis Research Center, Iran)*; Johanna A Otero (Fundación 
Oftalmológica de Santander, Colombia)*; Kim Overvad (Aarhus 
University, Denmark)*; Ellis Owusu-Dabo (Kwame Nkrumah University 
of Science and Technology, Ghana)*; Fred Michel Paccaud (UniSanté, 
Switzerland)*; Cristina Padez (University of Coimbra, Portugal)*; 
Elena Pahomova (University of Latvia, Latvia)*; Karina Mary de Paiva 
(Federal University of Santa Catarina, Brazil)*; Andrzej Pająk 
(Jagiellonian University Medical College, Poland)*; Domenico Palli 
(Institute for Cancer Research, Prevention and Clinical Network, Italy)*; 
Luigi Palmieri (Istituto Superiore di Sanità, Italy)*; Wen-Harn Pan 
(Academia Sinica, Taiwan)*; Songhomitra Panda-Jonas (Institute of 
Clinical and Scientific Ophthalmology and Acupuncture Jonas & Panda, 
Germany)*; Francesco Panza (IRCCS Ente Ospedaliero Specializzato in 
Gastroenterologia S. de Bellis, Italy)*; Mariela Paoli (University of the 
Andres, Venezuela)*; Dimitrios Papandreou (Zayed University, 
United Arab Emirates)*; Soon-Woo Park (Catholic University of Daegu, 
South Korea)*; Suyeon Park (Korea Centers for Disease Control and 
Prevention, South Korea)*; Winsome R Parnell (University of Otago, 
New Zealand)*; Mahboubeh Parsaeian (Tehran University of Medical 
Sciences, Iran)*; Patrick Pasquet (UMR CNRS-MNHN 7206, France)*; 
Nikhil D Patel (Jivandeep Hospital, India)*; Halyna Pavlyshyn 
(I Horbachevsky Ternopil National Medical University, Ukraine)*; 
Ivan Pećin (University Hospital Center Zagreb, Croatia)*; 
Mangesh S Pednekar (Healis-Sekhsaria Institute for Public Health, 
India)*; João M Pedro (Centro de Investigação em Saúde de Angola, 
Angola)*; Nasheeta Peer (South African Medical Research Council, 
South Africa)*; Sergio Viana Peixoto (Oswaldo Cruz Foundation Rene 
Rachou Research Institute, Brazil)*; Markku Peltonen (Finnish Institute 
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for Health and Welfare, Finland)*; Alexandre C Pereira (University of 
São Paulo, Brazil)*; Karen GDA Peres (Griffith University, Australia)*; 
Marco A Peres (National Dental Care Centre Singapore, Singapore)*; 
Annette Peters (Helmholtz Zentrum München, Germany)*; 
Janina Petkeviciene (Lithuanian University of Health Sciences, 
Lithuania)*; Niloofar Peykari (Ministry of Health and Medical Education, 
Iran)*; Son Thai Pham (Vietnam National Heart Institute, Vietnam)*; 
Rafael N Pichardo (Clínica de Medicina Avanzada Dr. Abel González, 
Dominican Republic)*; Iris Pigeot (Leibniz Institute for Prevention 
Research and Epidemiology–BIPS, Germany)*; Hynek Pikhart 
(University College London, UK)*; Aida Pilav (University of Sarajevo, 
Bosnia and Herzegovina)*; Lorenza Pilotto (Cardiovascular Prevention 
Centre Udine, Italy)*; Freda Pitakaka (Ministry of Health and Medical 
Services, Solomon Islands)*; Aleksandra Piwonska (National Institute of 
Cardiology, Poland)*; Andreia n Pizarro (University of Porto, Portugal)*; 
Pedro Plans-Rubió (Public Health Agency of Catalonia, Spain)*; 
Ozren Polašek (University of Split, Croatia)*; Miquel Porta (Institut 
Hospital del Mar d’Investigacions Mèdiques, Spain)*; Anil Poudyal 
(Nepal Health Research Council, Nepal)*; Farhad Pourfarzi 
(Ardabil University of Medical Sciences, Iran)*; Akram Pourshams 
(Tehran University of Medical Sciences, Iran)*; Hossein Poustchi 
(Tehran University of Medical Sciences, Iran)*; Rajendra Pradeepa 
(Madras Diabetes Research Foundation, India)*; Alison J Price (London 
School of Hygiene & Tropical Medicine, UK)*; Jacqueline F Price 
(University of Edinburgh, UK)*; Rui Providencia (University College 
London, UK)*; Soile E Puhakka (University of Oulu, Finland; Oulu 
Deaconess Institute Foundation, Finland)*; Maria Puiu (Victor Babes 
University of Medicine and Pharmacy Timisoara, Romania)*; 
Margus Punab (Tartu University Clinics, Estonia)*; Radwan F Qasrawi 
(Al-Quds University, Palestine)*; Mostafa Qorbani (Alborz University of 
Medical Sciences, Iran)*; Daniel Queiroz (Federal University of 
Pernambuco, Brazil)*; Tran Quoc Bao (Ministry of Health, Vietnam)*; 
Ivana Radić (University of Novi Sad, Serbia)*; Ricardas Radisauskas 
(Lithuanian University of Health Sciences, Lithuania)*; 
Salar Rahimikazerooni (Shiraz University of Medical Sciences, Iran)*; 
Mahfuzar Rahman (Pure Earth, Bangladesh)*; Olli Raitakari (University 
of Turku, Finland)*; Manu Raj (Amrita Institute of Medical Sciences, 
India)*; Ellina M Rakhimova (Ufa Eye Research Institute, Russia)*; 
Sudha Ramachandra Rao (National Institute of Epidemiology, India)*; 
Ambady Ramachandran (India Diabetes Research Foundation, India)*; 
Elisabete Ramos (University of Porto Medical School, Portugal)*; 
Lekhraj Rampal (Universiti Putra Malaysia, Malaysia)*; Sanjay Rampal 
(University of Malaya, Malaysia)*; Daniel A Rangel Reina (Instituto 
Conmemorativo Gorgas de Estudios de la Salud, Panama)*; Vayia Rarra 
(Sotiria Hospital, Greece)*; Cassiano Ricardo Rech (Federal University of 
Santa Catarina, Brazil)*; Josep Redon (University of Valencia, Spain)*; 
Paul Ferdinand M Reganit (University of the Philippines, Philippines)*; 
Valéria Regecová (Slovak Academy of Sciences, Slovakia)*; Luis Revilla 
(Universidad San Martín de Porres, Peru)*; Abbas Rezaianzadeh (Shiraz 
University of Medical Sciences, Iran)*; Robespierre Ribeiro (Minas 
Gerais State Secretariat for Health, Brazil; deceased)*; Elio Riboli 
(Imperial College London, UK)*; Adrian Richter (University Medicine 
Greifswald, Germany)*; Fernando Rigo (CS S. Agustín Ibsalut, Spain)*; 
Tobias F Rinke de Wit (Amsterdam Institute for Global Health and 
Development, Netherlands)*; Raphael M Ritti-Dias (Universidade Nove 
de Julho, Brazil)*; Cynthia Robitaille (Public Health Agency of Canada, 
Canada)*; Fernando Rodríguez-Artalejo (Universidad Autónoma de 
Madrid CIBERESP, Spain)*; María del Cristo Rodriguez-Perez (Canarian 
Health Service, Spain)*; Laura A Rodríguez-Villamizar (Universidad 
Industrial de Santander, Colombia)*; Ulla Roggenbuck (University of 
Duisburg-Essen, Germany)*; Rosalba Rojas-Martinez (National Institute 
of Public Health, Mexico)*; Dora Romaguera (CIBEROBN, Spain)*; 
Elisabetta L Romeo (Associazione Calabrese di Epatologia, Italy)*; 
Annika Rosengren (University of Gothenburg, Sweden; Sahlgrenska 
University Hospital, Sweden)*; Joel GR Roy (Statistics Canada, 
Canada)*; Adolfo Rubinstein (Institute for Clinical Effectiveness and 
Health Policy, Argentina)*; Jean-Bernard Ruidavets (Toulouse University 
School of Medicine, France)*; Blanca Sandra Ruiz-Betancourt (Instituto 
Mexicano del Seguro Social, Mexico)*; Maria Ruiz-Castell (Luxembourg 
Institute of Health, Luxembourg)*; Iuliia A Rusakova (Ufa Eye Research 
Institute, Russia)*; Paola Russo (National Research Council, Italy)*; 
Marcin Rutkowski (Medical University of Gdansk, Poland)*; 
Charumathi Sabanayagam (Singapore Eye Research Institute, 
Singapore)*; Hamideh Sabbaghi (Shahid Beheshti University of Medical 
Sciences, Iran)*; Harshpal S Sachdev (Sitaram Bhartia Institute of 
Science and Research, India)*; Alireza Sadjadi (Tehran University 
of Medical Sciences, Iran)*; Ali Reza Safarpour (Shiraz University of 
Medical Sciences, Iran)*; Sare Safi (Shahid Beheshti University of 
Medical Sciences, Iran)*; Saeid Safiri (Tabriz University of Medical 
Sciences, Iran)*; Olfa Saidi (University Tunis El Manar, Tunisia)*; 
Sibel Sakarya (Koç University, Turkey)*; Nader Saki (Ahvaz Jundishapur 
University of Medical Sciences, Iran)*; Benoit Salanave (French Public 
Health Agency, France)*; Eduardo Salazar Martinez (National Institute 
of Public Health, Mexico)*; Diego Salmerón (CIBER en Epidemiología y 
Salud Pública, Spain)*; Veikko Salomaa (Finnish Institute for Health 
and Welfare, Finland)*; Jukka T Salonen (University of Helsinki, 
Finland)*; Massimo Salvetti (University of Brescia, Italy)*; 
Jose Sánchez-Abanto (National Institute of Health, Peru)*; Susana Sans 
(Catalan Department of Health, Spain)*; Diana A Santos (Universidade 
de Lisboa, Portugal)*; Ina S Santos (Federal University of Pelotas, 
Brazil)*; Lèlita C Santos (Coimbra University Hospital Center, 
Portugal)*; Maria Paula Santos (University of Porto, Portugal)*; 
Rute Santos (University of Porto, Portugal)*; Jouko L Saramies 
(South Karelia Social and Health Care District, Finland)*; 
Luis B Sardinha (Universidade de Lisboa, Portugal)*; Giselle Sarganas 
(German Centre for Cardiovascular Research, Germany; Robert Koch 
Institute, Germany)*; Nizal Sarrafzadegan (Isfahan Cardiovascular 
Research Center, Iran)*; Thirunavukkarasu Sathish (McMaster 
University, Canada)*; Kai-Uwe Saum (German Cancer Research Center, 
Germany)*; Savvas Savva (Research and Education Institute of Child 
Health, Cyprus)*; Norie Sawada (National Cancer Center, Japan)*; 
Mariana Sbaraini (Universidade Federal do Rio Grande do Sul, Brazil)*; 
Marcia Scazufca (University of São Paulo Clinics Hospital, Brazil)*; 
Beatriz D Schaan (Universidade Federal do Rio Grande do Sul, Brazil)*; 
Herman Schargrodsky (Hospital Italiano de Buenos Aires, Argentina)*; 
Sabine Schipf (University Medicine Greifswald, Germany)*; 
Carsten O Schmidt (University Medicine Greifswald, Germany)*; 
Peter Schnohr (Copenhagen University Hospital, Denmark)*; 
Ben Schöttker (German Cancer Research Center, Germany)*; 
Sara Schramm (University of Duisburg-Essen, Germany)*; 
Constance Schultsz (Academic Medical Center of University of 
Amsterdam, Netherlands)*; Aletta E Schutte (University of 
New South Wales, Australia; The George Institute for Global Health, 
Australia)*; Sylvain Sebert (University of Oulu, Finland)*; Aye Aye Sein 
(Ministry of Health and Sports, Myanmar)*; Abhijit Sen (Center for Oral 
Health Services and Research Mid-Norway, Norway)*; Idowu O Senbanjo 
(Lagos State University College of Medicine, Nigeria)*; Sadaf G Sepanlou 
(Tehran University of Medical Sciences, Iran)*; Jennifer Servais 
(Statistics Canada, Canada)*; Svetlana A Shalnova (National Medical 
Research Centre for Therapy and Preventive Medicine, Russia)*; 
Teresa Shamah-Levy (National Institute of Public Health, Mexico)*; 
Morteza Shamshirgaran (Neyshabur University of Medical Sciences, 
Iran)*; Coimbatore Subramaniam Shanthirani (Madras Diabetes 
Research Foundation, India)*; Maryam Sharafkhah (Tehran University 
of Medical Sciences, Iran)*; Sanjib K Sharma (B P Koirala Institute of 
Health Sciences, Nepal)*; Jonathan E Shaw (Baker Heart and Diabetes 
Institute, Australia)*; Amaneh Shayanrad (Tehran University of Medical 
Sciences, Iran)*; Ali Akbar Shayesteh (Ahvaz Jundishapur University of 
Medical Sciences, Iran)*; Zumin Shi (Qatar University, Qatar)*; 
Kenji Shibuya (King’s College London, UK)*; Hana Shimizu-Furusawa 
(Nippon Medical School, Japan)*; Dong Wook Shin (Sungkyunkwan 
University, South Korea)*; Majid Shirani (Shahrekord University of 
Medical Sciences, Iran)*; Rahman Shiri (Finnish Institute of 
Occupational Health, Finland)*; Namuna Shrestha (Public Health 
Promotion and Development Organization, Nepal)*; Khairil Si-Ramlee 
(Ministry of Health, Brunei)*; Alfonso Siani (National Research Council, 
Italy)*; Rosalynn Siantar (Singapore Eye Research Institute, Singapore)*; 
Abla M Sibai (American University of Beirut, Lebanon)*; 
Caroline Ramos de Moura Silva (University of Pernambuco, Brazil)*; 
Diego Augusto Santos Silva (Federal University of Santa Catarina, 
Brazil)*; Mary Simon (India Diabetes Research Foundation, India)*; 
Judith Simons (St Vincent’s Hospital, Australia)*; Leon A Simons 
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(University of New South Wales, Australia)*; Michael Sjöström 
(Karolinska Institutet, Sweden; deceased)*; Jolanta Slowikowska-Hilczer 
(Medical University of Lodz, Poland)*; Przemyslaw Slusarczyk 
(International Institute of Molecular and Cell Biology, Poland)*; 
Liam Smeeth (London School of Hygiene & Tropical Medicine, UK)*; 
Hung-Kwan So (University of Hong Kong, China)*; 
Fernanda Cunha Soares (University of Pernambuco, Brazil)*; 
Eugène Sobngwi (University of Yaoundé 1, Cameroon)*; 
Stefan Söderberg (Umeå University, Sweden)*; Agustinus Soemantri 
(Diponegoro University, Indonesia; deceased)*; Reecha Sofat (University 
College London, UK)*; Vincenzo Solfrizzi (University of Bari, Italy)*; 
Mohammad Hossein Somi (Tabriz University of Medical Sciences, 
Iran)*; Emily Sonestedt (Lund University, Sweden)*; Yi Song (Peking 
University, China)*; Thorkild IA Sørensen (University of Copenhagen, 
Denmark)*; Elin P Sørgjerd (Norwegian University of Science and 
Technology, Norway)*; Maroje Sorić (University of Zagreb, Croatia)*; 
Charles Sossa Jérome (Institut Régional de Santé Publique, Benin)*; 
Aïcha Soumaré (University of Bordeaux, France)*; Bente Sparboe-Nilsen 
(Oslo Metropolitan University, Norway)*; Karen Sparrenberger 
(Universidade Federal do Rio Grande do Sul, Brazil)*; Jan A Staessen 
(University of Leuven, Belgium)*; Gregor Starc (University of Ljubljana, 
Slovenia)*; Bill Stavreski (Heart Foundation, Australia)*; 
Jostein Steene-Johannessen (Norwegian School of Sport Sciences, 
Norway)*; Peter Stehle (Bonn University, Germany)*; Aryeh D Stein 
(Emory University, USA)*; George S Stergiou (National and 
Kapodistrian University of Athens, Greece)*; Jochanan Stessman 
(Hadassah University Medical Center, Israel)*; Jutta Stieber (Helmholtz 
Zentrum München, Germany; deceased)*; Doris Stöckl (Helmholtz 
Zentrum München, Germany)*; Tanja Stocks (Lund University, 
Sweden)*; Jakub Stokwiszewski (National Institute of Public Health - 
National Institute of Hygiene, Poland)*; Karien Stronks (University of 
Amsterdam, Netherlands)*; Maria Wany Strufaldi (Federal University of 
São Paulo, Brazil)*; Machi Suka (The Jikei University School of 
Medicine, Japan)*; Chien-An Sun (Fu Jen Catholic University, Taiwan)*; 
Johan Sundström (Uppsala University, Sweden)*; Yn-Tz Sung 
(The Chinese University of Hong Kong, China)*; 
Paibul Suriyawongpaisal (Mahidol University, Thailand)*; Rody G Sy 
(University of the Philippines, Philippines)*; Holly E Syddall (University 
of Southampton, UK)*; René Charles Sylva (National Statistical Office, 
Cape Verde)*; Moyses Szklo (Johns Hopkins Bloomberg School of Public 
Health, USA)*; E Shyong Tai (National University of Singapore, 
Singapore)*; Mari-Liis Tammesoo (University of Tartu, Estonia)*; 
Abdonas Tamosiunas (Lithuanian University of Health Sciences, 
Lithuania)*; Eng Joo Tan (Deakin University, Australia)*; Xun Tang 
(Peking University, China)*; Frank Tanser (University of Lincoln, UK)*; 
Yong Tao (Peking University, China)*; Mohammed Rasoul Tarawneh 
(Ministry of Health, Jordan)*; Carolina B Tarqui-Mamani (National 
Institute of Health, Peru)*; Anne Taylor (University of Adelaide, 
Australia)*; Julie Taylor (University College London, UK)*; 
William R Tebar (Universidade Estadual Paulista, Brazil)*; 
Grethe S Tell (University of Bergen, Norway)*; Tania Tello (Universidad 
Peruana Cayetano Heredia, Peru)*; Yih Chung Tham (Singapore Eye 
Research Institute, Singapore)*; K R Thankappan (Central University of 
Kerala, India)*; Holger Theobald (Karolinska Institutet, Sweden)*; 
Xenophon Theodoridis (Aristotle University of Thessaloniki, Greece)*; 
Lutgarde Thijs (University of Leuven, Belgium)*; Mikael Thinggaard 
(University of Southern Denmark, Denmark)*; Nihal Thomas (Christian 
Medical College Vellore, India)*; Barbara Thorand (Helmholtz Zentrum 
München, Germany)*; Betina H Thuesen (Bispebjerg and Frederiksberg 
Hospital, Denmark)*; Erik J Timmermans (Amsterdam Public Health 
Research Institute, Netherlands)*; Dwi H Tjandrarini (National Institute 
of Health Research and Development, Indonesia)*; Anne Tjonneland 
(Danish Cancer Society Research Center, Denmark)*; Ulla Toft 
(Bispebjerg and Frederiksberg Hospital, Denmark)*; Hanna K Tolonen 
(Finnish Institute for Health and Welfare, Finland)*; Janne S Tolstrup 
(University of Southern Denmark, Denmark)*; Murat Topbas (Karadeniz 
Technical University, Turkey)*; Roman Topór-Madry (Jagiellonian 
University Medical College, Poland)*; María José Tormo (Health Service 
of Murcia, Spain)*; Michael J Tornaritis (Research and Education 
Institute of Child Health, Cyprus)*; Maties Torrent (Institut 
d’Investigacio Sanitaria Illes Balears, Spain)*; Laura Torres-Collado 
(CIBER en Epidemiología y Salud Pública, Spain)*; Giota Touloumi 
(National and Kapodistrian University of Athens, Greece)*; 
Pierre Traissac (French National Research Institute for Sustainable 
Development, France)*; Areti Triantafyllou (Aristotle University of 
Thessaloniki, Greece)*; Dimitrios Trichopoulos (Harvard T H Chan 
School of Public Health, USA; deceased)*; Antonia Trichopoulou 
(Hellenic Health Foundation, Greece)*; Oanh TH Trinh (University of 
Medicine and Pharmacy at Ho Chi Minh City, Vietnam)*; Atul Trivedi 
(Government Medical College, India)*; Lechaba Tshepo (Sefako 
Makgatho Health Science University, South Africa)*; Shoichiro Tsugane 
(National Cancer Center, Japan)*; Azaliia M Tuliakova (Ufa Eye Research 
Institute, Russia)*; Marshall K Tulloch-Reid (The University of the 
West Indies, Jamaica)*; Fikru Tullu (Addis Ababa University, Ethiopia)*; 
Tomi-Pekka Tuomainen (University of Eastern Finland, Finland)*; 
Jaakko Tuomilehto (Finnish Institute for Health and Welfare, Finland)*; 
Maria L Turley (Ministry of Health, New Zealand)*; Gilad Twig (Tel-Aviv 
University, Israel; Israel Defense Forces Medical Corps, 
Israel)*; Per Tynelius (Karolinska Institutet, Sweden)*; 
Christophe Tzourio (University of Bordeaux, France)*; Peter Ueda 
(Karolinska Institutet, Sweden)*; Eunice Ugel (Universidad Centro-
Occidental Lisandro Alvarado, Venezuela)*; Hanno Ulmer (Medical 
University of Innsbruck, Austria)*; Hannu MT Uusitalo (University of 
Tampere Tays Eye Center, Finland)*; Gonzalo Valdivia (Pontificia 
Universidad Católica de Chile, Chile)*; Damaskini Valvi (Icahn School of 
Medicine at Mount Sinai, USA)*; Rob M van Dam (National University 
of Singapore, Singapore)*; Bert-Jan van den Born (University of 
Amsterdam, Netherlands)*; Johan Van der Heyden (Sciensano, 
Belgium)*; Yvonne T van der Schouw (Utrecht University, 
Netherlands)*; Koen Van Herck (Ghent University, Belgium)*; 
Hoang Van Minh (Hanoi University of Public Health, Vietnam)*; 
Natasja M Van Schoor (VU University Medical Center, Netherlands)*; 
Irene GM van Valkengoed (University of Amsterdam, Netherlands)*; 
Elisabeth M van Zutphen (VU University Medical Center, Netherlands)*; 
Dirk Vanderschueren (Katholieke Universiteit Leuven, Belgium)*; 
Diego Vanuzzo (Cardiovascular Prevention Centre Udine, Italy)*; 
Anette Varbo (Copenhagen University Hospital, Denmark; University of 
Copenhagen, Denmark)*; Senthil K Vasan (University of Southampton, 
UK)*; Tomas Vega (Consejería de Sanidad Junta de Castilla y León, 
Spain)*; Toomas Veidebaum (National Institute for Health 
Development, Estonia)*; Gustavo Velasquez-Melendez (Universidade 
Federal de Minas Gerais, Brazil)*; Giovanni Veronesi (University of 
Insubria, Italy)*; WM Monique Verschuren (National Institute for Public 
Health and the Environment, Netherlands)*; Roosmarijn Verstraeten 
(Institute of Tropical Medicine, Belgium)*; Cesar G Victora (Federal 
University of Pelotas, Brazil)*; Lucie Viet (National Institute for Public 
Health and the Environment, Netherlands)*; Salvador Villalpando 
(National Institute of Public Health, Mexico)*; Paolo Vineis (Imperial 
College London, UK)*; Jesus Vioque (University Miguel Hernandez, 
Spain)*; Jyrki K Virtanen (University of Eastern Finland, Finland)*; 
Sophie Visvikis-Siest (Université de Lorraine, France)*; 
Bharathi Viswanathan (Ministry of Health, Seychelles)*; Tiina Vlasoff 
(North Karelia Center for Public Health, Finland)*; Peter Vollenweider 
(Lausanne University Hospital, Switzerland; University of Lausanne, 
Switzerland)*; Ari Voutilainen (University of Eastern Finland, Finland)*; 
Alisha N Wade (University of the Witwatersrand, South Africa)*; 
Janette Walton (Munster Technological University, 
Ireland)*; Elvis OA Wambiya (African Population and Health Research 
Center, Kenya)*; Wan Mohamad Wan Bebakar (Universiti Sains 
Malaysia, Malaysia)*; Wan Nazaimoon Wan Mohamud (Institute for 
Medical Research, Malaysia)*; Rildo de Souza Wanderley Júnior 
(University of Pernambuco, Brazil)*; Ming-Dong Wang (Public Health 
Agency of Canada, Canada)*; Ningli Wang (Capital Medical University 
Beijing Tongren Hospital, China)*; Qian Wang (Xinjiang Medical 
University, China)*; Xiangjun Wang (Shanghai Educational 
Development Co Ltd, China)*; Ya Xing Wang (Capital Medical 
University, China)*; Ying-Wei Wang (Ministry of Health and Welfare, 
Taiwan)*; S Goya Wannamethee (University College London, UK)*; 
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